Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,494 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intervention 2 - Placebo Clear all

Conditions: Type 2 Diabetes
Interventions: Vitamin D, Placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 30 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes
Interventions: CT-868 as SC Injection, Placebo as SC Injection, Active Comparator as SC Injection; Drug
Lead sponsor: Carmot Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Cocaine Dependence
Interventions: Doxazosin, Modafinil, cocaine, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
Interventions: Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 40 Years to 69 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: NSAID (Non-Steroidal Anti-Inflammatory Drug), Lumbar Spine Fusion, Ketorolac, Postoperative Pain
Interventions: Ketorolac, Naproxen, Standard Postoperative Pain Management; Drug · Other
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: COPD, Emphysema or COPD, Chronic Bronchitis
Interventions: Treatment Then Placebo, Placebo Then Treatment; Procedure
Lead sponsor: Lung Institute; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes, Pre-Diabetes
Interventions: water-soluble cinnamon extract (Cinnulin PF); Drug
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Travis Air Force Base, California • Eglin Air Force Base, Florida • Offutt Air Force Base, Nebraska + 1 more

Conditions: Opioid Dependence
Interventions: 2-4 of the drugs listed below; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Binge Drinking, HIV
Interventions: Placebo, Naltrexone, Medical Management (MM) counseling for alcohol use:, Urinalysis for novel alcohol biochemical markers:, Behavioral survey measurements:, Dried Blood Spot (DSB) Testing for Phosphatidylethanol, Ecological Momentary Assessment; Drug · Behavioral · Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions: Sildenafil citrate (open label), Testosterone gel, Placebo gel; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions: Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT); Drug · Diagnostic Test
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Temple, Texas

Conditions: Migraine
Interventions: Lu AG09222, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 28
States / cities: Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more

Conditions: Food Allergies
Interventions: Food Drops: Food Allergens (peptides); Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 4 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Brain Tumor
Interventions: Bright Light Exposure, Dim Light Exposure, Cognitive Assessment; Behavioral · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Eosinophilic Esophagitis
Interventions: AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension; Drug
Lead sponsor: AQILION AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Microvascular Coronary Artery Disease
Interventions: SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • Jacksonville, Florida • Wellington, Florida + 3 more

Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Immune Surveillance
Interventions: Agaricus blazei, Reishi, Turkey Tail, Placebo; Dietary Supplement · Other
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Insomnia
Interventions: Baseline surveys, Cognitive testing and EMAs, Actiwatch, suvorexant (or placebo), Placebo; Behavioral · Device · Drug + 1 more
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism Spectrum Disorder, Autistic Disorder, Autism, Asperger's Syndrome, Pervasive Development Disorders
Interventions: Folinic Acid and placebo, Folinic Acid; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 3 Years to 14 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Alcohol Abuse, Alcoholism
Interventions: Ondansetron, Placebo, BASICS Plus; Drug · Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 25 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Columbia, Maryland

Conditions: Uterine Atony, Uterine Atony With Hemorrhage, Postpartum Hemorrhage, Cesarean Section Complications
Interventions: Calcium chloride, Saline placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Pacifica, California

Conditions: Separation Anxiety Disorder, Generalized Anxiety Disorder, Social Phobia
Interventions: Acoustic Neuromodulation (ANM); Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 7 Years to 17 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Overweight, Metabolic Syndrome X
Interventions: Placebo, Cr-400, Cr-800, PE-500, PE-1000; Dietary Supplement
Lead sponsor: Kerry Group P.L.C; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: College Station, Texas

Search by objective public record fields.

Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

Complementary Combination Therapy for Cocaine Dependence

Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

NSAIDS Following Elective Lumbar Spine Fusion

Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD

Cinnamon Trial-lIfestyle iNtervention Plus Water-soluble Cinnamon Extract On loweriNg Blood Glucose in Pre-diabetics

Drug Discrimination in Methadone-Maintained Humans Study 2

Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)

Effect of Testosterone in Men With Erectile Dysfunction

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Sublingual Immunotherapy for Food Allergy

Systematic Light Exposure in Pediatric Brain Tumor Survivors

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

Clinical Trial: Rapid Immune Modulating Effects

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

A Folinic Acid Intervention for Autism Spectrum Disorders

Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults

Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery

Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders

Impact of Chromium, Phyllanthus Emblica, and Shilajit on Cardiovascular Health, Fitness, and Weight Loss During Exercise and Diet Programs